Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV003442124 | SCV004169595 | likely pathogenic | not provided | 2023-05-16 | criteria provided, single submitter | clinical testing | Canonical splice site variant predicted to result in an in-frame loss of the adjacent exon in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 32244026) |
Invitae | RCV000856685 | SCV004642169 | pathogenic | Glycogen storage disease IXa1 | 2023-03-08 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 694638). Disruption of this splice site has been observed in individuals with clinical features of PHKA2-related conditions (PMID: 32244026; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change affects a donor splice site in intron 9 of the PHKA2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PHKA2 are known to be pathogenic (PMID: 7711737, 10330341). For these reasons, this variant has been classified as Pathogenic. |
Molecular Diagnostics Laboratory, |
RCV000856685 | SCV000999210 | pathogenic | Glycogen storage disease IXa1 | 2019-11-11 | no assertion criteria provided | clinical testing | |
QSNICH Molecular Lab, |
RCV003127491 | SCV002559896 | likely pathogenic | Increased hepatic glycogen content | 2022-07-01 | no assertion criteria provided | clinical testing |